University Heatlh Network
Toronto, Ontario, Canada
Access Creation for Hemodialysis: Association With Structural Changes of the Heart
Status
Completed
Phase
Not applicable
Enrollment
84
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to determine if the creation of a fistula or a graft plays a role in the development of heart disease for patients undergoing hemodialysis
Full detailed description
Patients with end stage renal disease are at 18-20 times greater risk of dying from cardiovascular disease as the general population. Both traditional and non-traditional cardiovascular risk factors are thought to be important. Of the non-tradtional cardiovascular risk factors, creation of an arteriovenous fistula or graft for the purposes of a blood access for hemodialysis may contribute to an elevation in BNP and left ventricular hypertrophy - both factors that have been associated with an increased risk of mortality Prior to access creation and at one month and one year post access creation - samples for BNP will be collected Prior to access creation and at one year post access creation - echocardiography will be performed
Interventions
Treatment arms and agents.
No intervention details reported.
Timeline
From registration to results.
First posted
Aug 24, 2006
Study start
Apr 2002
Primary completion
Not reported
Study completion
Feb 2007
Results posted
Not reported
Registry updated
Nov 13, 2023
Outcomes
What the study measures.
Primary outcomes
Not reported in the indexed record.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1)Hemodialysis 2)high risk for heart failure (DM, age\>50, and/or systolic dysfunction) 3) first arteriovenous fistula/graft 4) informed consent 5) technically adequate echocardiogram 6) stable hgb(\>100) 7) stable mineral metabolism (normal calcium, phosphate \<2.1mmol/L, PTH\>50pmol/L) Exclusion Criteria: 1)Expected survival \<1 year 2) Expected to get a living donor transplant in one year 3)primary access failure 4) ARF
Study locations
1 registered sites.
Canada. Showing up to 24 locations stored in the fast local snapshot.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Nesiritide.
NCT IDStudyPhase / statusEnrollmentUpdated
PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Measurement Of NT-proBNP to Predict Outcomes in Surgery
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Venous Excess and Lung Ultrasound During Continuous Kidney Replacement Therapy in Critically Ill Patients
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Spironolactone Therapy in Chronic Stable Right HF Trial
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Secondary Use of PARALLEL-HF Data
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.